Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,738 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Failure Chronic Clear all
Completed Phase 3 Interventional Results available

Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia

NCT00236977
View directory record Official record
Conditions
Anemia
Interventions
Venofer, Ferrous Sulfate
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Valley Forge, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 24, 2026, 10:27 PM EDT
Completed Phase 2 Interventional

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

NCT06272487
View directory record Official record
Conditions
High Cardiovascular Risk, Hypertension
Interventions
Zilebesiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
139
States / cities
Alexander City, Alabama • Daphne, Alabama • Foley, Alabama + 115 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 24, 2026, 10:27 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Empagliflozin in ESKD - A Feasibility Study

NCT05687058
View directory record Official record
Conditions
Kidney Failure, Chronic, Heart Failure
Interventions
Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing, Empagliflozin 10 mg daily dosing
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 24, 2026, 10:27 PM EDT
Completed No phase listed Observational

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

NCT01431326
View directory record Official record
Conditions
Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions
The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
Up to 21 Years
Enrollment
3,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
43
States / cities
Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 24, 2026, 10:27 PM EDT
Terminated Phase 3 Interventional Results available

The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis

NCT00503698
View directory record Official record
Conditions
Chronic Kidney Disease, End-Stage Renal Disease
Interventions
somatropin, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
209
States / cities
Alexander City, Alabama • Birmingham, Alabama • Madison, Alabama + 177 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 24, 2026, 10:27 PM EDT
Completed No phase listed Observational

Oxidative Stress and Hemodialysis Access Failure

NCT00410449
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis
Interventions
Alpha tocopherol
Drug
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 24, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease

NCT01574326
View directory record Official record
Conditions
Hyperphosphatemia, Chronic Kidney Disease
Interventions
Placebo, Sevelamer carbonate
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Up to 18 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 24, 2026, 10:27 PM EDT
Terminated Not applicable Interventional

Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury

NCT04877847
View directory record Official record
Conditions
Contrast-induced Nephropathy, Chronic Kidney Diseases
Interventions
Low-frequency therapeutic ultrasound (LOTUS), LOTUS System with Ultrasound Disabled
Device
Lead sponsor
Sonogenix
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Detroit, Michigan • Petoskey, Michigan • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 24, 2026, 10:27 PM EDT
Completed Phase 4 Interventional Results available

Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients

NCT02781649
View directory record Official record
Conditions
End-Stage Renal Disease, Hepatitis C
Interventions
Zepatier, Ribavirin, Sofosbuvir
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 24, 2026, 10:27 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)

NCT00048451
View directory record Official record
Conditions
Renal Insufficiency, Chronic
Interventions
paricalcitol
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
18
States / cities
Tucson, Arizona • Pasadena, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2006 · Synced Oct 24, 2026, 10:27 PM EDT
Completed Not applicable Interventional Results available

Supporting Self-Management of Healthy Behaviors in Chronic Kidney Disease

NCT04858295
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hypertension
Interventions
Texting, mHealth app
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 24, 2026, 10:27 PM EDT
Recruiting Not applicable Interventional

CAPABLE Transplant

NCT06326905
View directory record Official record
Conditions
Quality of Life, Depression, End Stage Renal Disease, Disability Physical
Interventions
CAPABLE Transplant- Open Label Pilot, CAPABLE Transplant- Randomized Control Trial
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 24, 2026, 10:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

NCT02062203
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AKB-6548 (therapeutic dose), AKB-6548 (supratherapeutic dose), Placebo, Moxifloxacin
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 24, 2026, 10:27 PM EDT
Recruiting Not applicable Interventional

Collaborative Learning to Achieve Refined Interventions for Emory: Kidney Disease

NCT06693661
View directory record Official record
Conditions
Kidney Diseases
Interventions
Kidney Health Coaching, Usual Care
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 24, 2026, 10:27 PM EDT
Recruiting Not applicable Interventional

Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula

NCT06516653
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
VasQ, Arteriovenous fistula creation for dialysis vascular access
Device · Procedure
Lead sponsor
Laminate Medical Technologies
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Long Beach, California • Sarasota, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 24, 2026, 10:27 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

NCT06866236
View directory record Official record
Conditions
Chronic Kidney Diseases, Acute Kidney Injury, Kidney Failure
Interventions
QRX-3
Drug
Lead sponsor
Ebima Clifford Okundaye
Industry
Eligibility
18 Years to 90 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pasedena, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 24, 2026, 10:27 PM EDT
Completed Phase 1 Interventional

Two Vitamin D Dosing Strategies in Children With Chronic Kidney Disease

NCT01909115
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
1000 IU of Vitamin D3, 4000 IU of Vitamin D3
Drug
Lead sponsor
Emory University
Other
Eligibility
9 Years to 21 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 24, 2026, 10:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)

NCT01970176
View directory record Official record
Conditions
Cardiomyopathy, Renal Impairment
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 24, 2026, 10:27 PM EDT
Completed Not applicable Interventional

Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis

NCT00004285
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Standard dose, low flux hemodialysis, Standard dose, high flux hemodialysis, High dose, low flux hemodialysis, High dose, high flux hemodialysis
Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years
Enrollment
1,846 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 24, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

NCT01630889
View directory record Official record
Conditions
Chronic Kidney Disease, End Stage Renal Disease, Anemia
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
4
States / cities
Riverside, California • Greenbelt, Maryland • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 24, 2026, 10:27 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis

NCT00548249
View directory record Official record
Conditions
End-Stage Renal Disease (ESRD)
Interventions
Standard Bicarbonate Solution, Soluble Ferric Pyrophosphate
Device · Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
27
States / cities
Tempe, Arizona • Hacienda Heights, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 24, 2026, 10:27 PM EDT
Not yet recruiting Not applicable Interventional

Handgrip Exercise Training and CKD

NCT07094906
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
Isometric handgrip exercise training, Sham Training
Device
Lead sponsor
Emory University
Other
Eligibility
45 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 24, 2026, 10:27 PM EDT
Recruiting Phase 3 Interventional

CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease

NCT05422534
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
CoQ10, Placebo, HB-HIIT, Observational
Dietary Supplement · Drug · Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Sacramento, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 24, 2026, 10:27 PM EDT
Completed Not applicable Interventional

Efficacy and Safety of the DASH Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study

NCT02059811
View directory record Official record
Conditions
Hypertension, Chronic Kidney Disease
Interventions
DASH Diet, Control Diet
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2014 · Synced Oct 24, 2026, 10:27 PM EDT